Influence of Placebo on Intratissue Percutaneous Electrolysis in Patellar Tendinopathy

Launched by UNIVERSITY OF VALENCIA · Nov 17, 2020

Keywords

ClinConnect Summary

This clinical trial is investigating how a treatment called Intratissue Percutaneous Electrolysis (IPE) works for people with chronic patellar tendinopathy, which is a condition that causes pain in the knee area, especially when jumping or running. The researchers want to see if a placebo, which is a non-active treatment, affects the results of IPE. They also aim to understand how IPE might change a person’s perception of pain.

To participate in this study, you need to be at least 18 years old and have had knee pain for at least three months, with specific symptoms related to patellar tendinopathy. However, if you’ve had knee surgery, received certain injections in the last six months, or have certain health conditions, you may not be eligible. If you join the trial, you will likely receive the IPE treatment and be monitored for how it affects your pain and overall knee function. This study is currently recruiting participants of all genders aged 18 and older.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years old or older
• • presenting the following signs and symptoms of patellar tendinopathy: pain when jumping, landing, running o changing direction, pain at the inferior pole of the patella, Victorian Institute of Sport Assessment-Patella (VISA-P) score \<80, symptoms duration of at least 3 months.
• Exclusion Criteria:
• • prior knee surgery
• • patients having received local corticosteroids injection in the tendon within the preceding 6 months
• • patients presenting any inflammatory disease, metabolic bone disease, type II diabetes, fibromyalgia, hypercholesterolemia, pregnancy or chemotherapy within the 3 months prior to the study.